NCT02976350

Completed

Hormone Deficiency in Heart Failure With Preserved Ejection ...

Federico II University Source

Compare

Other study identifiers

Sponsor study identifier

HormoneHFpEF001

Study Type

observational

Actual enrollment (reported)

35

Locations

1 country

Sites

1

Timeline

Study Start

January 2015

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

April 2015

Actual (reported)

Study Completion

September 2015

Actual (reported)

Brief Summary

The objective of this study is to describe the prevalence of Multiple Hormone Deficiencies in Heart Failure with preserved Ejection Fraction.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 35 participants
Study completion date: September 2015
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
January 2015
Date type not reported
This date has not been verified as actual or estimated.
Primary Completion
April 2015
Actual (reported)
Study Completion
September 2015
Actual (reported)
First Submitted
May 14, 2016
Actual (reported)
First Posted
November 29, 2016
Actual (reported)

Last Updated: November 29, 2016
Status Verified: November 2016
Last Update Submitted: November 23, 2016

Conditions

Heart Failure Hormone Deficiencies

Keywords

Heart failureHeart failure with preserved ejection fractionGH deficiencyTestosterone deficiencyLow- T3 syndromeMultiple Hormone Deficiencies

Outcome Measures

Primary Outcomes (1)

Prevalence of Hormone deficiency
1 months

Study Arms (1)

Patients with HFpEF

Male patients with heart failure with preserved ejection fraction

Eligibility Criteria

Age18 Years+

Sexmale

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Male patients with stable chronic heart failure with preserved ejection fraction

You may qualify if:

Male patients of affected by CHF, secondary to ischemic or idiopathic dilated cardiomyopathy

Sponsors & Collaborators

Federico II University
Otherlead

Study Sites (1)

Antonio Cittadini

Naples, Italy

Biospecimen

Retention: SAMPLES WITHOUT DNA

serum for determination of hormonal levels

MeSH Terms

Conditions

Heart FailureDwarfism, PituitaryEuthyroid Sick Syndromes

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesDwarfismBone Diseases, DevelopmentalBone DiseasesMusculoskeletal DiseasesBone Diseases, EndocrineHypopituitarismPituitary DiseasesHypothalamic DiseasesBrain DiseasesCentral Nervous System Diseases

Study Officials

Antonio Cittadini, Professor
Federico II University
STUDY CHAIR

Enrollment

35 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: CROSS SECTIONAL
Target Duration: 6 Months
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Clinical Professor

Study Record Dates

First Submitted

May 14, 2016

First Posted

November 29, 2016

Study Start

January 2015

Date type not reported

This date has not been verified as actual or estimated.

NCT01951638

Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)

Phase 2Completed

NCT01840059

Renal Denervation in Heart Failure With Preserved Ejection Fraction

Phase 2Completed

NCT02661841

Effectiveness of Lung Impedance Guided Preemptive Therapy of Chronic Heart Failure Patients With Preserved Ejection Fraction (LVEF ≥ 45%) in Our Hospital's Outpatient Clinic

Not ApplicableUnknown

NCT01542502

Pilot Feasibility Study of the Safety and Efficacy of Anakinra in Heart Failure With Preserved Ejection Fraction

Not ApplicableCompleted

NCT02598505

Indacaterol in Heart Failure Patients: Any Role on Lung Fluid Regulation

Phase 3Completed

NCT02840799

Effect of KNO3 Compared to KCl on Oxygen UpTake in Heart Failure With Preserved Ejection Fraction (KNO3CK OUT HFPEF)

Phase 2Completed

left ventricle ejection fraction \> 50% or more

You may not qualify if:

severe liver disease
serum creatinine levels \>2.5 mg/dl
history of active cancer with life expectancy below 1 year acute coronary syndrome in the previous 6 months

Contact the study team to confirm eligibility.

Nervous System Diseases

Endocrine System Diseases

Thyroid Diseases

Primary Completion

April 2015

Actual (reported)

Study Completion

September 2015

Actual (reported)

Last Updated

November 29, 2016

Record last verified: 2016-11

Data Sharing

IPD Sharing: Will share

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT02976350
Data provider: ClinicalTrials.gov
Source updated: 2016-11-29
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:18:33 UTC

Locations

IT(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

Patients with HFpEF

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations